title: Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases.
abstract: Inflammatory bowel diseases (IBD) are chronic, relapsing disorders affecting gastrointestinal (GI) tract and associated with intestinal mucosa damage and inflammation. The principal therapeutic goals in IBD include control of the intestinal inflammation and treatment of the major symptoms, mainly abdominal pain and diarrhea. Current therapeutic strategies for IBD rely on the use of non-specific anti-inflammatory agents and immunosuppressive drugs (e.g. aminosalicylates, monoclonal antibodies, and antibiotics), which cause severe side effects, and - in a significant number of patients - do not induce long-term benefits. In this review, we summarize the epidemiology and the most important risk factors of IBD, including genetic, immunological and environmental. Our main focus is to discuss pharmacological targets for current and future treatments of IBD.
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Marta
authors.initials: M
authors.lastname: Sobczak
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Adam
authors.initials: A
authors.lastname: Fabisiak
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Natalia
authors.initials: N
authors.lastname: Murawska
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Ewelina
authors.initials: E
authors.lastname: Wesołowska
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Paulina
authors.initials: P
authors.lastname: Wierzbicka
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Marcin
authors.initials: M
authors.lastname: Wlazłowski
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Marta
authors.initials: M
authors.lastname: Wójcikowska
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Hubert
authors.initials: H
authors.lastname: Zatorski
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Marta
authors.initials: M
authors.lastname: Zwolińska
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland. Electronic address: jakub.fichna@umed.lodz.pl.
authors.forename: Jakub
authors.initials: J
authors.lastname: Fichna
mesh_terms: D015746:Abdominal Pain / Q000188:drug therapy / Q000209:etiology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology; D018450:Disease Progression; D015195:Drug Design; D020022:Genetic Predisposition to Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D012307:Risk Factors
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents
keywords: Crohn's disease; Inflammatory bowel diseases; Risk factors; Ulcerative colitis